Arvinas, Inc. Presents Phase 1 Data on LRRK2 Drug ARV-102 in Seoul
What happened
Arvinas, Inc. presented novel Phase 1 clinical trial data for ARV-102, an investigational PROTAC degrader designed to target leucine-rich repeat kinase 2 (LRRK2), at the 2026 International Congress of Parkinson’s Disease and Movement Disorders in Seoul, Korea. The findings showed improvements in an objective measure of impaired eye movement in patients with Parkinson’s disease. The research also indicated a correlation between reductions in LRRK2 cerebrospinal fluid biomarkers and changes in oculomotor and synaptic biomarkers.
From manilatimes.net
Why it matters
The data provides evidence that ARV-102 reaches the central nervous system and degrades LRRK2, supporting its continued evaluation as a potential therapeutic approach for neurodegenerative diseases associated with LRRK2 dysregulation. Although the study was not designed to assess clinical efficacy, the results show encouraging exploratory dose-related changes in ocular saccadic hypome.
From manilatimes.net
Who's involved
- SeoulLocation where the clinical research data was presented.
- NasdaqStock exchange where Arvinas, Inc. is listed.
- Lee Jae MyungPresident of South Korea, whose governance is centered in Seoul.
- MarketBeatAmerican personal finance blog that tracks financial data.
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- NasdaqSpeculative
The market price of Arvinas, Inc. on Nasdaq could change due to the positive clinical trial results.